Precigen Inc. (NASDAQ: PGEN) reported Q4 EPS of ($0.22), $0.07 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $19.33 million versus the consensus estimate of $21.2 million.

"2021 promises to be another transformative year for our company with important data readouts and trial initiations anticipated for our key programs," said Helen Sabzevari, PhD, President and CEO of Precigen. "Through a combination of fiscal discipline and our recent capital raise, we have sufficient cash on hand to support our capital needs into 2023. We will continue to work diligently to advance our pipeline of innovative therapies and technology platforms as quickly as possible and our entire team remains committed to achieving this goal on behalf of the patients that motivate us every day. We look forward to providing updates in the coming months."

For earnings history and earnings-related data on Precigen Inc. (PGEN) click here.